Illumina (NASDAQ:ILMN) Director Keith Meister Sells 104,393 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 104,393 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director directly owned 3,500,048 shares in the company, valued at $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Illumina Stock Down 1.2%

ILMN traded down $1.76 during trading on Thursday, hitting $143.24. The company had a trading volume of 2,006,814 shares, compared to its average volume of 1,636,244. The company has a market capitalization of $21.67 billion, a PE ratio of 26.04, a PEG ratio of 2.40 and a beta of 1.42. Illumina, Inc. has a one year low of $78.55 and a one year high of $155.53. The firm’s 50-day moving average price is $128.31 and its 200 day moving average price is $129.43. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the business earned $0.97 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Capital World Investors increased its stake in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. State Street Corp grew its stake in Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after buying an additional 190,324 shares during the last quarter. WCM Investment Management LLC grew its stake in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares during the last quarter. AQR Capital Management LLC grew its stake in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after buying an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after buying an additional 130,139 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on ILMN shares. Royal Bank Of Canada set a $170.00 price target on shares of Illumina in a research note on Thursday. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Thursday. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Finally, Canaccord Genuity Group lowered their price objective on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $137.75.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.